Our class of non-invasive proprietary cancer diagnostic tests are currently being developed by BioTime subsidiary OncoCyte Corporation for the diagnosis of cancer. Clinical validation studies are currently underway for applications in lung, breast, and bladder cancers. We expect that more frequent testing for screening and monitoring cancer recurrence will be a growing market. Interim clinical validation study data was presented at the annual meeting of the American Association for Cancer Research (AACR) in April 2015, which demonstrated a high level of sensitivity and specificity in the detection of urothelial carcinoma, the most common type of bladder cancer. Interim clinical validation data for lung cancer was presented at the American Thoracic Society (ATS) international conference in May of 2015.
Our cancer diagnostic products are based on the relatively simple detection of a unique set of “markers” or molecules, some discovered through BioTime’s stem cell research, that have been associated with different cancer types. OncoCyte is initially focusing on the detection of lung, breast, and bladder cancers because the early detection of these cancers address high unmet medical needs and may help avoid costly biopsy procedures. Our cancer diagnostic products could ultimately address the market need to screen up to 10 million patients per year for lung cancer, 3.5 million patients a year for breast cancer, and up to 1.5 million patients per year for bladder cancer.
These markers are protected by certain patent applications designed to protect OncoCyte’s commercial activities in a wide range of cancer types.